# Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

> **NCT05303038** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Breast Cancer in the Liver

## Interventions

- **COMBINATION_PRODUCT:** Cryoablation Combined with Tirelizumab and Bevacizumab

## Key facts

- **NCT ID:** NCT05303038
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303038, "Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05303038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*